The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
- PMID: 11473066
- DOI: 10.2337/diacare.24.8.1335
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
Abstract
Objective: In patients with type 2 diabetes, intensive glucose regulation, although effective for microangiopathy, has not been shown to have unambiguous preventive effects on the occurrence of cardiovascular disease. Patients with diabetes show a characteristic dyslipidemia (high triglyceride level, low HDL cholesterol level). Aggressive reduction of triglycerides might be an effective method to reduce the cardiovascular risk in these patients.
Research design and methods: A double-blind, placebo-controlled, randomized study to assess the effect of 30 weeks of administration of atorvastatin 10 and 80 mg on plasma triglyceride levels in 217 patients with type 2 diabetes and fasting triglyceride levels between 1.5 and 6.0 mmol/l.
Results: Administration of atorvastatin 10 and 80 mg resulted in significant reductions (25 and 35%, respectively) of plasma triglyceride levels (both P < 0.001). The difference between 10 and 80 mg was not statistically significant (P > 0.5). Atorvastatin 10 mg provided significant reductions from baseline in total cholesterol (-30%, P < 0.001), LDL cholesterol (-40%, P < 0.001), and apolipoprotein B (-31%, P < 0.001), and significantly increased HDL cholesterol from baseline by 6% (P < 0.005). Atorvastatin 80 mg had a similar effect on HDL cholesterol (+5.2%, P < 0.005) but significantly decreased total cholesterol (-40%, P < 0.001), LDL cholesterol (-52%, P < 0.001), and apolipoprotein B (-40%, P < 0.001) more than atorvastatin 10 mg (P < 0.005). The side effects of atorvastatin 10 and 80 mg were similar and did not differ from the patients receiving placebo.
Conclusions: Administration of 10- and 80-mg doses of atorvastatin provides similar, significant reductions from baseline in triglyceride levels in patients with type 2 diabetes. A higher dose of atorvastatin improves cholesterol-related parameters. Both doses were well tolerated in this patient population.
Similar articles
-
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.Metabolism. 2002 Mar;51(3):334-42. doi: 10.1053/meta.2002.30510. Metabolism. 2002. PMID: 11887170 Clinical Trial.
-
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023. Clin Ther. 2008. PMID: 19167589 Clinical Trial.
-
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.Diabetes Obes Metab. 2000 Dec;2(6):355-62. doi: 10.1046/j.1463-1326.2000.00106.x. Diabetes Obes Metab. 2000. PMID: 11225965 Clinical Trial.
-
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.Drugs. 2001;61(12):1835-81. doi: 10.2165/00003495-200161120-00012. Drugs. 2001. PMID: 11693468 Review.
-
[Statins in diabetic hyperlipidemia].Wien Med Wochenschr. 1999;149(5-6):139-43. Wien Med Wochenschr. 1999. PMID: 10408005 Review. German.
Cited by
-
Ongoing clinical trials of the pleiotropic effects of statins.Vasc Health Risk Manag. 2005;1(1):29-40. doi: 10.2147/vhrm.1.1.29.58937. Vasc Health Risk Manag. 2005. PMID: 17319096 Free PMC article. Review.
-
Hyperlipidemia: a new therapeutic target for diabetic neuropathy.J Peripher Nerv Syst. 2009 Dec;14(4):257-67. doi: 10.1111/j.1529-8027.2009.00237.x. J Peripher Nerv Syst. 2009. PMID: 20021567 Free PMC article. Review.
-
Prevalence of statin intolerance: a meta-analysis.Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015. Eur Heart J. 2022. PMID: 35169843 Free PMC article.
-
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.Drugs. 2005;65(1):137-52. doi: 10.2165/00003495-200565010-00015. Drugs. 2005. PMID: 15610062 Review.
-
Lipids and diabetic nephropathy.Curr Diab Rep. 2006 Dec;6(6):455-62. doi: 10.1007/s11892-006-0079-7. Curr Diab Rep. 2006. PMID: 17118229 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical